1) Perros F, Montani D, Dorfmüller P, et al:Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81-88, 2008
2) Schermuly RT, Dony E, Ghofrani HA, et al:Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821, 2005
3) Hoeper MM, Barst RJ, Bourge RC, et al:Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Results of the Randomized IMPRES Study. Circulation 127:1128-1138, 2013
4) Klein M, Schermuly RT, Ellinghaus P, et al:Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118:2081-2090, 2008
5) Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al:Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 33:278-291, 2008
6) Gomberg-Maitland M, Maitland ML, Barst RJ, et al:A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 87:303-310, 2010
7) Kimura G, Kataoka M, Inami T, et al:Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. Pulm Pharmacol Ther 44:46-49, 2017
8) Kataoka M, Yanagisawa R, Fukuda K, et al:Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. Cardiology 123:172-174, 2012
9) Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, et al:Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 32:232-235, 2008